MedPath

Prospective Registration of Patient Data and Quality of Life in Eye Melanoma Patients

Recruiting
Conditions
Uveal Melanoma
Interventions
Other: Quality of life questionnaires
Other: Discrete choice experiment
Other: Shared decision-making analysis
Other: Impact of side-effects analysis
Registration Number
NCT05377957
Lead Sponsor
Leiden University Medical Center
Brief Summary

PROQEM is a prospective cohort study among patients diagnosed with uveal melanoma to assess quality of life before and in the first five years after treatment.

Detailed Description

PROQEM is a prospective observational cohort study wherein patients with uveal melanoma are registered at diagnosis and are requested to fill in an array of questionaires before treatment and at 3, 6, 12, 24, 36 and 60 months after treatment. A comprehensive overview of the impact of their disease and treatment on quality of life is obtained by systematic assessment of the psychological impact of the initial diagnosis, eye symptoms, physical, emotional, social and role functioning.

In addition, the PROQEM has a substudy called the PROQEM-pco (Preferences, Choices and Outcomes) for the subgroup of patients who are eligible for both proton therapy and enucleation. They are invited to participate in research on patient preferences and shared decision-making. The consultations wherein the treatment decision is made are audiotaped and data on perceived shared decision-making, preferences, decision satisfaction and -regret are collected by questionaires at baseline and in the first 36 months after treatment.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Age ≥18 years
  • Clinical or pathological diagnosis of a melanoma of the choroid or ciliary body
  • No signs of metastasis after staging procedures with at least an X-thorax, blood test and an ultrasound of the liver
  • Treatment by brachytherapy, proton therapy or enucleation
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Proton therapyDiscrete choice experimentUveal melanoma patients treated with proton therapy
EnucleationQuality of life questionnairesUveal melanoma patients treated with enucleation
BrachytherapyQuality of life questionnairesUveal melanoma patients treated with Ruthenium-106 plaque brachytherapy
Proton therapyQuality of life questionnairesUveal melanoma patients treated with proton therapy
Proton therapyImpact of side-effects analysisUveal melanoma patients treated with proton therapy
EnucleationDiscrete choice experimentUveal melanoma patients treated with enucleation
EnucleationImpact of side-effects analysisUveal melanoma patients treated with enucleation
Proton therapyShared decision-making analysisUveal melanoma patients treated with proton therapy
EnucleationShared decision-making analysisUveal melanoma patients treated with enucleation
Primary Outcome Measures
NameTimeMethod
Uveal melanoma-related quality of life5 years

EORTC QLQ-OPT30

Health-related quality of life5 years

EORTC QLQ-C30

General quality of life5 years

EQ-5D-5L

Impact of the diagnosis and treatment of uveal melanoma on mental health2 years

Impact of events scale

Secondary Outcome Measures
NameTimeMethod
Shared decision-making1 year

Audiotape, iSHARE, satisfaction with decision scale, decision regret scale

Patient preferences for outcomes of proton therapy and enucleationCross-sectional at baseline

Discrete choice experiment

Impact of side-effects of treatment for uveal melanoma3 years

Questionnaire specifically developed for uveal melanoma

Trial Locations

Locations (1)

Leiden University Medical Center

🇳🇱

Leiden, Zuid-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath